In a report issued on August 7, Gena Wang from Barclays maintained a Hold rating on PTC Therapeutics (PTCT), with a price target of $43. The company’s shares closed on Friday at $47.10, close to its 52-week high of $48.99.
According to TipRanks.com, Wang is a 5-star analyst with an average return of 18.3% and a 50.6% success rate. Wang covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Ionis Pharmaceuticals Inc, and Crispr Therapeutics AG.
PTC Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $50.75, representing a 7.7% upside. In a report issued on August 6, Cowen & Co. also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $48.99 and a one-year low of $27.53. Currently, PTC Therapeutics has an average volume of 705.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology.
